FDA's Selective Response to the IoM Drug Safety Report

FDA says its plan to improve the post-marketing drug safety system embraces most of the recommendations made by the Institute of Medicine in a 2006 report. But in several respects, the agency's response isn't exactly what IoM had in mind.

At a press conference held to announce the Food & Drug Administration’s response to the Institute of Medicine’s report on drug safety, the agency’s top brass stressed that FDA is following the committee’s recommendations in its ongoing plan to improve the post-marketing drug safety system.

At first glance, it certainly looks that way: in response to the 25 recommendations from the IoM committee’s September 2006...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Agency Leadership

More from Pink Sheet